Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows ...

Levies on Americans’ daily prescriptions and other medicines could raise costs, spur rationing and lead to shortages of ...

Proposed tariffs on pharmaceutical imports could destabilize U.S. generic drug supply, warns Dr. Scott Gottlieb.

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Because RNAs are so central to our biology, they are also drivers of a wide array of diseases. Defects in how RNA is produced ...